- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02842814
Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus (PRESS)
September 30, 2022 updated by: Peking Union Medical College Hospital
Evaluation and Prediction of Relapse Risk After Glucocorticoid Withdrawal in Patients With Stable Systemic Lupus Erythematosus: An Open-labeled Multi-centric Randomized Controlled Study From China
Whether and when systemic lupus erythematosus (SLE) patients with stable disease should withdraw glucocorticoid (GC)?
How about the relapse risk?
What are the risk factors for disease flare?
All the above are unclear.
Long-course GC treatment has a lot of side-effects even in a sustaining low dose.
The aim of this study is to explore the relapse risk after GC withdrawal in SLE patients with stable disease more than one year and to establish a predictive model for flare risk stratification.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a relapsing-remitting course.
For patients in remission, glucocorticoid (GC) is used to be maintained in a low dose for a long time in fear of disease flare.
Long-term GC could bring a lot of side-effects even in a low dose.
Whether and when patients with stable disease should withdraw GC? How about the relapse risk?
What are the risk factors for disease flare?
All the above remain unclear.
The aim of this study is to explore the relapse risk after GC withdrawal in SLE patients with stable disease and to establish a predictive model for risk stratification.
Meanwhile the investigators aim to testify the effects of hydroxychloroquine in preventing SLE relapse.
This study is an open-labeled randomized controlled clinical trial.
Study Type
Interventional
Enrollment (Actual)
333
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Anhui Provincial Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Xiangya Hospital of Central South University
-
-
Liaoning
-
Shenyang, Liaoning, China, 110004
- Shengjing Hospital of China Medical University
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 830001
- People's Hospital of Xinjiang Uygur Autonomous Region
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- SLE diagnosis fulfilled the Systemic Lupus International Collaborating Clinic revision of the American College of Rheumatology Classification Criteria for SLE
- Disease stabilized ≥ 1 year
- SELENA-SLEDAI ≤ 3
- Anti-double strand DNA negative by IF measurement and ≤ 200IU/ml by ELISA method
- Complement 3 (C3) ≥ 0.5*lower limit of the normal range, and fluctuation of the C3 is less than 10% within the last year
- 24 hour urine protein ≤ 0.5g
- Prednisone (or equivalent) ≤ 7.5mg/d for more than 6 months
- No use of immunosuppressants including CsA, MMF, CTX, FK506, LEF, MTX in recent 6 months. But hydroxychloroquine (HCQ) is permitted and should be in use
- Never use biologic agents including Rituximab, Belimumab, Epratuzumab and so on
- No severe organ involvement in recent 2 years including lupus encephalosis, diffused alveolar hemorrhage, thrombotic thrombocytopenia purpura, rapid progressive glomerulonephritis, severe thrombocytopenia, severe hemolytic anemia, myocardial involvement, myeleterosis or severe peripheral neuropathy
Exclusion Criteria:
- Active SLE
- In pregnancy or breastfeeding, plan for pregnancy
- Plan or has been on a surgery in recent 6 months
- Current infection
- History of malignancy
- Severe organ dysfunction or other complications
- Unable to follow up
- Inappropriate to be enrolled
- Psoriasis, porphyria, arrhythmia or eye diseases that contradict with HCQ usage
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Full withdrawal
Intervention: 'Drug free'.
|
Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
|
Experimental: GC withdrawal
Intervention: 'HCQ' .
|
Glucocorticoid(GC) treatment is stopped in stable SLE patients.
Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
Other Names:
|
Experimental: No withdrawal
Intervention: 'GC+HCQ' .
|
Glucocorticoid(GC) is kept no more than 7.5mg/d.
Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of subjects with mild to moderate Lupus flare evaluated by modified SELENA-SLEDAI flare index (SFI)
Time Frame: 33 weeks
|
The SFI includes three elements: the SELENA-SLEDAI score (range 0 ~105, with 0 indicating inactive disease and ); an assessment of new or worsening disease activity, medication changes, and hospitalizations that not captured with the use of the SLEDAI; and the score on the physician's global-assessment (PGA) visual-analogue scale (range, 0 to 3, 1=mild, 2=moderate, 3=severe); Mild to moderate flare by SFI is defined as appearance of one of the following: a change in SLEDAI>3 points but≤12 points; or new onset/worse of cutaneous/ mucosal injury (discoid, photosensitivity, profundus, cutaneous vasculitis, bullous lupus, Nasopharyngeal ulcers), serositis (pleuritis and/or pericarditis), arthritis, SLE associated fever; or the need to increase prednisone dosage to no more than 0.5 mg/kg/day; or the need to add hydroxychloroquine or NSAIDs with no increase in the dose GC; or an increment of PGA ranges from 1.0 to 2.5.
|
33 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of subjects with a SELENA-SLEDAI maintaining at <4 points
Time Frame: 33 weeks
|
33 weeks
|
|
Mean change in PGA
Time Frame: 33 weeks
|
The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity; A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity
|
33 weeks
|
• Percent of subjects with at least one B in any system evaluated with The British Isles Lupus Activity Group (BILAG) scoring system
Time Frame: 33 weeks
|
BILAG includes 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and haematological).
A to E scoring is based on the physician's intention to treat: Grade A: treatment requiring any of the following 1) high dose oral glucocorticoids, eg: prednisolone>20mg/day; 2) intravenous pulse glucocorticoids, eg: pulse methylprednisolone ≥ 500 mg;3)systemic immunomodulators (include biologicals, immunoglobulins and plasmapheresis);4) therapeutic high dose anticoagulation, eg: warfarin INR 3 - 4; Grade B: treatment requiring any of the following treatment:1) low dose oral glucocorticoids, eg: prednisolone ≤ 20mg/day; 2) intramuscular or intra-articular or soft tissue glucocorticoids injection; 3) topical glucocorticoids;4) topical immunomodulators; 5) antimalarials or thalidomide;6) symptomatic therapy; eg: NSAIDs; Grade C: mild disease; Grade D: inactive now but previously affected; Grade E: systems never involved
|
33 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Xuan Zhang, MD, Peking Union Medical College Hospital
- Study Chair: Xuan Zhang, MD, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2016
Primary Completion (Actual)
September 28, 2022
Study Completion (Actual)
September 28, 2022
Study Registration Dates
First Submitted
June 3, 2016
First Submitted That Met QC Criteria
July 20, 2016
First Posted (Estimate)
July 25, 2016
Study Record Updates
Last Update Posted (Actual)
October 3, 2022
Last Update Submitted That Met QC Criteria
September 30, 2022
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Disease Attributes
- Connective Tissue Diseases
- Lupus Erythematosus, Systemic
- Recurrence
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Hydroxychloroquine
- Glucocorticoids
Other Study ID Numbers
- ZS-906
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Drug free
-
Medtronic VascularCompleted
-
China Medical University HospitalChina Medical University, China; Qualitix Clinical Research Co., Ltd.; Tian-I...Not yet recruitingCOVID-19 | Influenza Viral InfectionsTaiwan
-
PregLem SACompletedUterine FibroidsPoland, Spain, Austria, Belgium
-
Sterna Biologicals GmbH & Co. KGCompleted
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH); Henry Ford... and other collaboratorsRecruiting
-
Sterna Biologicals GmbH & Co. KGCompletedMild to Moderate Atopic DermatitisGermany
-
The Affiliated Hospital of Hangzhou Normal UniversityNot yet recruitingCirrhosis | Metabolic Dysfunction-associated Fatty Liver Disease
-
University Hospital, RouenNot yet recruiting
-
Manchanda Medical ClinicNot yet recruitingProstatic Hyperplasia